[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583114":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":44,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":27,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Label Treatment Arm","EXPERIMENTAL","Dose escalating study with a Follow-up (washout) Period:\n\nTotal study period of the open-label study: 14 weeks Screening Period: up to 4 weeks Treatment Period (20 mg TID): 4 weeks Treatment Period (40 mg TID): 4 weeks Treatment Period (60 mg TID): 4 weeks Follow-up (washout) Period: 2 weeks after treatment period ends",[13],"Drug: Artesunate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Artesunate","Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Roham Zamanian, MD","STUDY_DIRECTOR",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Stanford","California","94305","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-122.16608,37.42411,{"lat":37,"lon":36},[40],{"name":23,"role":41,"phone":42,"phoneExt":20,"email":43},"CONTACT","(650) 725-7061","roham.zamanian@stanford.edu",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Joseph C. Wu","Director, Stanford Cardiovascular Institute","100583114","phase-1-a-study-evaluating-the-safety-and-tolerability-of-artesunate-in-patients-with-pulmonary-arterial-hypertension-100583114",false,"NCT06872112","A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","(STOP-PAH)","Inclusion Criteria\n\n* Each participant must meet the following criteria to be enrolled in this study:\n* Adults aged 18 to 75 years.\n* WHO functional class I, II\u002FIII despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.\n\nExclusion Criteria\n\n* Participants who meet any of the following criteria will be excluded from the study.\n* Participants with serious concomitant morbidity per investigator assessment.","ALL","18 Years","60 Years",{"count":60,"type":61},15,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.",[67],"Pulmonary Arterial Hypertension (PAH)",[69,17,70],"Pulmonary Arterial Hypertension","PAH","2026-04-21",{"date":73,"type":74},"2026-04-23","ACTUAL",{"date":76,"type":74},"2026-04-01",{"date":78,"type":61},"2029-01-01",{"name":46,"class":6},1]